# US 11,993,787 B2 · Neural cell extracellular vesicles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,993,787 B2
- Document ID: US11993787B2
- Status: Granted
- Kind: B2
- Application number: 15/770,881
- Filed: 2016-11-16
- Published: 2018-11-15
- Granted: 2024-05-28
- Earliest claimed: 2015-11-18
- Assignees: University of Georgia Research Foundation, Inc.; Aruna Bio, Inc.
- Applicants: University of Georgia Research Foundation, Inc.; Aruna Bio, Inc.
- Inventors: Steven L. Stice; Robin Lynn Webb; Tracy A. Stice
- Web page: https://patentgrep.com/patent/US11993787B2

## CPC

- C12N 5/0619: {Neurons}
- A61K 9/5176: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/5123)}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- C12N 5/0622: {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
- C12N 5/0623: {Stem cells}
- A61K 9/5068: {Cell membranes or bacterial membranes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 2506/02: from embryonic cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2533/30: Synthetic polymers
- G01N 33/56966: {Animal cells}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein are neural extracellular vesicles (EVs) and methods of using these EVs in the treatment of spinal cord injury, stroke, and traumatic brain injury and neurodegenerative diseases.

## Claims

### Claim 1

A pharmaceutical composition comprising a therapeutically effective amount of extracellular vesicles (EVs) obtained from non-transformed human neural progenitor cells that are capable of differentiating into neurons, astrocytes and oligodendrocytes in vitro, and a pharmaceutically acceptable carrier, wherein the EVs comprise melanoma-associated chondroitin sulfate proteoglycan (MCSP), pentraxin-3 (PTX3), angiopoietin-1, insulin-like growth factor-binding protein 2 (IGFBP2), macrophage colony-stimulating factor, and ecto-5′-nucleotidase (NT5E), and wherein the EVs comprise an exogenous agent selected from the group consisting of an siRNA, an antisense oligonucleotide, a peptide, a protein, an antibody, and a small molecule.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the EVs comprise an exogenous siRNA.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the EVs comprise an exogenous antisense oligonucleotide.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the EVs comprise an exogenous peptide or an exogenous protein.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the EVs comprise an antibody.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the EVs comprise a small molecule.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the EVs are exosomes.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises about 1 mg to about 750 mg of EVs.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the EVs are about 20 nm to 10 μm in size.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the EVs are about 25 nm to about 250 nm in size.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein the neural progenitor cells are obtained from human pluripotent stem cells.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, wherein the neural progenitor cells are obtained from human induced pluripotent stem cells.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, wherein the neural progenitor cells are obtained from human embryonic stem cells.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, wherein the neural progenitor cells are SOX1+, SOX2+ and OCT4−.